Nasdaq · Biotech stocks database
TSHA (Taysha Gene Therapies Inc.) stock: $4.10, $1.34B market cap, $422.8M cash, $961.4M EV, $1.49B fully diluted market cap. Next expected readout: Mar-27. Lead program: TSHA-102 (Rett Syndrome), Phase 3. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $422.8M |
|---|---|
| Debt | $47.3M |
| Net cash | $375.5M |
| Enterprise value | $961.4M |
| Basic shares | 326.1M shares |
| Fully diluted shares | 362.5M shares |
| Fully diluted market cap | $1,486.2M |
| Cash per share | $1.30 |
| Quarterly burn | $40.4M |
| Cash runway | 11.3 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.
Cap table as of 2025-12-31.
Loading TSHA daily closes…
TSHA-102 · Est. Apr 1, 2027 · half midpoint · guided in 7 wks